UCB News

UCB presents key data from Alzheimer's and Parkinson's disease research programs at AD/PD 2025

- 8 scientific abstracts reflect ongoing commitment to advancing the science and improving outcomes for people living with Alzheimer's and Parkinson's disease
- In Alzheimer's disease, data include subgroup analysis of the TOGETHER Phase 2a trial, investigating the safety, efficacy, and tolerability of bepranemab, an investigational anti-tau antibody targeting the mid-region epitope of the tau protein[1, 2]
- In Parkinson's disease, data include early insights into development program for UCB7853[3,4], an anti-alpha-synuclein antibody, and glovadalen (UCB0022), an orally available, selective, positive allosteric modulator of the D1 receptor (D1 PAM)[5]

Brussels, Belgium – 1 April 2025 – 7AM CET – UCB, a global biopharmaceutical company, today announced it will present 8 scientific abstracts, including 3 late-breaker oral presentations, highlighting key data from its innovative neurodegeneration research programs in Parkinson's and Alzheimer's disease, at this year's AD/PD 2025 meeting, Vienna, Austria, April 1-4, 2025.

"We are excited to present data on many aspects of our science and patient-driven neurodegeneration research program at AD/PD, highlighting promising insights into the underlying mechanisms of Alzheimer's and Parkinson's disease. The findings represent an important step forward in our efforts to develop effective treatments, bringing us closer to addressing these devastating neurodegenerative conditions," said Alistair Henry, Chief Scientific Officer, UCB.

In Alzheimer's disease, topline results from the TOGETHER phase 2a trial of bepranemab were released in October 2024 - the first study to provide evidence for clinical efficacy of anti-tau therapy in Alzheimer's disease[2] – and a subgroup analysis of this data is presented at AD/PD.[1]

In Parkinson's disease, UCB's research program includes investigating mechanisms to inhibit the misfolding and propagation of alpha-synuclein - processes believed to underlie the spread of neurodegeneration. Alongside this, the company is advancing research into new therapies for symptom control, recognizing the diverse needs of each patient throughout their disease trajectory. Assets include UCB7853, currently under investigation for preventing extracellular alpha-synuclein spread, and glovadalen (UCB0022), an orally available, brain-penetrant, small molecule, designed to enhance the potency of dopamine 'when and where needed' to activate the dopamine D1 receptor and thereby improve symptom control.[6,7]

Data at AD/PD include results from ORCHESTRA, a phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage Parkinson's disease.[8] UCB previously announced this study did not meet its primary or secondary clinical endpoints.[9]

Inspired by patients.
Driven by science.

Date of preparation: March 2025
GL-07-2500004

UCB News

Data presentations at AD/PD

Alzheimer's disease

- Barton M, et al. Phase II study of bepranemab in people with prodromal-mild Alzheimer's disease: Population subgroup analysis. (Late-breaker oral presentation)
- Byrnes W, et al. Safety MRI and volumetric MRI results from TOGETHER, a double-blind, placebo-controlled phase II study of bepranemab in prodromal-mild Alzheimer's disease. (Late-breaker oral presentation)

Parkinson's disease

- Carson S, et al. Results from ORCHESTRA, a phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage Parkinson's disease. (Late-breaker oral presentation)
- Downey P, et al. A preclinical evaluation of UCB7853, an anti-alpha-synuclein antibody in clinical development for Parkinson's disease. (Poster presentation)
- Kremer P, et al. Phase I study results: UCB7853 safety, tolerability and pharmacokinetics in healthy participants (single-ascending dose) and people with Parkinson's disease (multiple-ascending doses). (Poster presentation)
- Biagioni M, et al. Designing a patient-informed trial: ATLANTIS Phase II study of the D1 receptor PAM, UCB0022, in advanced Parkinson's disease. (Poster presentation)
- Morel T, et al. First qualitative assessment of the clinical meaningfulness of MDS-UPDRS Part III in early-stage Parkinson's disease. (Poster presentation)
- Williamson N, et al. Qualitative patient experience of advanced Parkinson's disease: A conceptual model of symptoms and health-related quality of life impacts. (Poster presentation)

The safety and efficacy of bepranemab, minzasolmin, glovadalen, and UCB7853 have not been established, and they are not currently approved for use in this indication by any regulatory authority worldwide.

For further information, contact UCB:

Global Communications
Nick Francis
T: +44 7769 307745
nick.francis@ucb.com

Global Corporate Communications
Laurent Schots
T: +32.2.559.92.64
laurent.schots@ucb.com

Investor Relations
Antje Witte
T: +32.2.559.94.14
antje.witte@ucb.com

Inspired by patients.
Driven by science.

Date of preparation: March 2025
GL-07-2500004

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements
This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following

Date of preparation: March 2025
GL-07-2500004

the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

References:

1. Barton M, et al. Phase II study of bepranemab in people with prodromal-mild Alzheimer's disease: Population subgroup analysis. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.
2. Barton M, et al. Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild AD. Presented at: 17th Clinical Trials on Alzheimer's Disease (CTAD); 2024 October 29 - November 1; Madrid, Spain.
3. Downey P, et al. A preclinical evaluation of UCB7853, an anti-alpha-synuclein antibody in clinical development for Parkinson's disease. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.
4. Kremer P, et al. Phase I study results: UCB7853 safety, tolerability and pharmacokinetics in healthy participants (single-ascending dose) and people with Parkinson's disease (multiple-ascending doses). Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.
5. Biagioni M, et al. Designing a patient-informed trial: ATLANTIS Phase II study of the D1 receptor PAM, UCB0022, in advanced Parkinson's disease. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.
6. https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB7853. Accessed March 2025.
7. https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB0022. Accessed March 2025.
8. Carson S, et al. Results from ORCHESTRA, a phase II proof-of-concept study assessing the efficacy and safety of minzasolmin in people with early-stage Parkinson's disease. Presented at: AD/PD; 2025 April 1-5; Vienna, Austria.
9. UCB Corporate Website. https://www.ucb.com/newsroom/press-releases/article/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb-parkinson-s-research-program. Accessed March 2025.

Date of preparation: March 2025
GL-07-2500004